



THROMBOLUX

QUALITY REASSURANCE

Making platelet activation status a priority is critical for achieving quality standards.

Results from a study on the potential impact of ThromboLUX-based inventory management at a US adult academic hospital.¹

Prioritizing platelet activation status is critical to preserving a life-saving resource

Transfusing resting platelets instead of activated platelets is integral to reducing the number of transfusions needed and increasing the time between transfusions. And for certain patients, like those with acute myeloid leukemia, this could ultimately mean the difference between life and death. Implementing a platelet management policy that includes transfusing the right platelets in the right patients can save both money and lives.

STUDY

The ThromboLUX-based inventory management study demonstrated that allocating the right platelets to the right patients leads to:

- **Reduced number of transfusions**
- **Fewer complex cases**
- **Lower costs**


STUDY OBJECTIVE



The main objective objective was to demonstrate improved transfusion outcomes in hematology-oncology patients by avoiding activated platelet transfusions. Clinical transfusion outcomes were measured as **1)** count increment and **2)** time to next transfusion.

STUDY DESIGN

Over the 100-day quality improvement initiative, ThromboLUX was used as part of routine practice in the blood bank. ThromboLUX is a 5-minute walk-away test to definitively determine activation status².

- **Resting platelets** were allocated to hematology-oncology patients requiring prophylactic transfusions.
- **Activated platelets** were allocated to actively bleeding surgical and trauma patients.





Patients receiving a transfusion with activated platelets typically received 7 subsequent transfusions compared to patients receiving resting platelets².

Activated	Resting	Median excess transfusions	95% Confidence interval
9	2	7	0 to 10

As complex cases are reduced so are transfusions and costs.

Cost per transfusion	Reduction of complex cases	Reduction of transfusions per patient	Transfusions saved annually	Expected annual savings
\$4,890	88%**	43%**	772**	\$3,775,080**

* In individual cases

** Extrapolated to full compliance with resting platelet allocation


Allocating the right platelets to the right patients helps make the most of a precious commodity



Resting platelets retain their discoid shape and are lifesaving for the most vulnerable patients—those with cancer.

Potential impact of resting platelets on cancer patients

- Significantly reduced number of transfusions
- Reduced chance of immune refractoriness



Activated platelets have changed to an amorphous form through normal processes and are ideal for cold storage and use in trauma patients.

Potential impact of activated platelets on cancer patients

- Reduced platelet count increments, increasing the need for more infusions
- Increased chance of refractoriness due to increased number of infusions
- May interfere with certain immunotherapies, complicating treatment

Identifying and distributing platelet products based on activation status can result in improved patient outcomes and cost savings²

The ThromboLUX System lets you assess activation status right when you get the product. Quickly. Safely. Definitively.

It's time to take control over platelet variability with ThromboLUX. For more information or to read the full study, please visit:

THROMBOLUX.COM